MUMBAI: Pharma major Elder Pharmaceuticals today said it has entered into an alliance with the Spanish Pharma company Laboraties Farmaceuticos Rovi S.A, to market Heparins (anti-thrombotics) in India for the treatment and prevention of diseases like deep vein thrombosis and pulmonary embolism.
Initially Elder and Rovi jointly would introduce the USFDA approved product ‘Bemiparin´ for the prevention and treatment of thrombo-embolic venous diseases. In India, Bemiparin would be launched with the brand name of HIBOR, the company informed the BSE.
“Anti-thrombotics constitute an important niche market for Elder Pharmaceuticals and we wanted to bring the most effective product range in this category to India,” Elder Pharma Director (International) Alok Saxena said.
The total anti-thrombotic market in India is estimated at Rs 130 crore and the company hopes to grab 8 - 10% market share in the first year of its launch.